Losartan - Bristol-Myers Squibb/Merck & Co
Alternative Names: Cozaar; Cozaarex; DUP 753; Lortaan; Losaprex; Losartan potassium; MK 954; Neo Lotan; Nu-Lotan; OscaarLatest Information Update: 05 Nov 2023
At a glance
- Originator Bristol-Myers Squibb
- Developer Banyu; M S Jacovides & Co; Merck & Co; Merck Sharp & Dohme; Neopharmed Gentili; S Riesel; sigma-tau SpA
- Class Antihypertensives; Biphenyl compounds; Heart failure therapies; Imidazoles; Ischaemic heart disorder therapies; Small molecules; Tetrazoles
- Mechanism of Action Angiotensin type 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Diabetic nephropathies; Heart failure; Hypertension
Most Recent Events
- 11 Apr 2021 Discontinued - Phase-III for Hypertension (In children, In infants) in USA, Romania, Spain, Lithuania, United Kingdom, Peru, Mexico, Guatemala, Colombia, Chile, Brazil, Philippines, Russia, Norway, India, Argentina, Hungary (PO)
- 08 Jun 2012 Merck & Co. completes enrolment in its Phase-III trial for Hypertension (in children and infants aged 6 months to 6 years) in USA, European Union, Latin America, India, Norway, Philippines and Russia (NCT00756938)
- 26 Jan 2012 Generic equivalent available in Canada for Hypertension & Diabetic nephropathies